Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Ecallantide for the treatment of acute attacks in hereditary angioedema.

Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE.

N Engl J Med. 2010 Aug 5;363(6):523-31. doi: 10.1056/NEJMoa0905079.

2.

Response time for ecallantide treatment of acute hereditary angioedema attacks.

Riedl M, Campion M, Horn PT, Pullman WE.

Ann Allergy Asthma Immunol. 2010 Dec;105(6):430-436.e2. doi: 10.1016/j.anai.2010.09.005.

PMID:
21130380
3.

Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.

Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE.

J Allergy Clin Immunol. 2011 Jul;128(1):153-159.e4. doi: 10.1016/j.jaci.2011.03.006.

PMID:
21481442
4.

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.

Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE.

Ann Allergy Asthma Immunol. 2010 Jun;104(6):523-9. doi: 10.1016/j.anai.2010.04.012.

PMID:
20568386
5.

Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.

Stolz LE, Sheffer AL.

Expert Rev Clin Immunol. 2012 Jan;8(1):25-32. doi: 10.1586/eci.11.81.

PMID:
22149337
6.

Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.

Bernstein JA, Shea EP, Koester J, Iarrobino R, Pullman WE.

Allergy. 2012 Sep;67(9):1173-80. doi: 10.1111/j.1398-9995.2012.02864.x.

7.

Use of ecallantide in pediatric hereditary angioedema.

MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R.

Pediatrics. 2013 Aug;132(2):e490-7. doi: 10.1542/peds.2013-0646.

8.

Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.

Stolz LE, Horn PT.

Drugs Today (Barc). 2010 Aug;46(8):547-55. doi: 10.1358/dot.2010.46.8.1507205. Review.

PMID:
20830315
9.

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.

Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE.

Allergy Asthma Proc. 2013 Mar-Apr;34(2):155-61. doi: 10.2500/aap.2013.34.3653. Erratum in: Allergy Asthma Proc. 2013 May-Jun;34(3):291.

PMID:
23484891
10.

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.

Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T.

J Allergy Clin Immunol. 2007 Aug;120(2):416-22.

PMID:
17559913
11.

Ecallantide for treatment of acute attacks of hereditary angioedema.

Martello JL, Woytowish MR, Chambers H.

Am J Health Syst Pharm. 2012 Apr 15;69(8):651-7. doi: 10.2146/ajhp110227. Review.

PMID:
22472866
12.

Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.

Banta E, Horn P, Craig TJ.

Allergy Asthma Proc. 2011 Jul-Aug;32(4):319-24. doi: 10.2500/aap.2011.32.3440.

PMID:
21781409
13.

Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.

Craig TJ, Li HH, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, Stolz LE, Biedenkapp J, Chyung Y.

J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):206-212.e4. doi: 10.1016/j.jaip.2014.09.001.

14.

FDA approves kallikrein inhibitor to treat hereditary angioedema.

Thompson CA.

Am J Health Syst Pharm. 2010 Jan 15;67(2):93. doi: 10.2146/news100005. No abstract available.

PMID:
20065259
15.

Therapeutic approaches in hereditary angioedema.

Antoniu SA.

Clin Rev Allergy Immunol. 2011 Aug;41(1):114-22. doi: 10.1007/s12016-011-8254-2. Review.

PMID:
21279474
16.

Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.

Bernstein JA, Qazi M.

Expert Rev Clin Immunol. 2010 Jan;6(1):29-39. Review.

PMID:
20383888
17.

Ecallantide: in acute hereditary angioedema.

Garnock-Jones KP.

Drugs. 2010 Jul 30;70(11):1423-31. doi: 10.2165/11205850-000000000-00000. Review.

PMID:
20614949
18.

Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.

MacGinnitie AJ, Campion M, Stolz LE, Pullman WE.

Allergy Asthma Proc. 2012 Mar-Apr;33(2):178-85. doi: 10.2500/aap.2012.33.3528.

PMID:
22525395
19.

Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.

Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE.

Ann Allergy Asthma Immunol. 2013 Mar;110(3):184-188.e2. doi: 10.1016/j.anai.2012.12.007.

PMID:
23548529
20.

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.

Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtułowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Bernstein JA.

J Allergy Clin Immunol. 2009 Oct;124(4):801-8. doi: 10.1016/j.jaci.2009.07.017.

PMID:
19767078

Supplemental Content

Support Center